Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia
Source: SeekingAlpha
2025-12-09 14:15:16 ET
More on Novartis
- Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
- Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy - Slideshow
- Novartis AG (NVS) Shareholder/Analyst Call Transcript
- Novartis inks $1.7 billion drug target agreement with UK’s Relation Therapeutics
- Notable analyst calls this week: Novartis, Albemarle and Zscaler among top picks
Read the full article on Seeking Alpha
For further details see:
Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia
Novartis AG
NASDAQ: NVS
NVS Trading
0.14% G/L:
$143.57 Last:
367,989 Volume:
$142.47 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
